Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors

Molecular Oncology

Volumn 7, Issue 5, 2013, Pages 944-954

  Lun, Xueqing ^a   Ruan, Yibing ^a   Jayanthan, Aarthi ^a   Liu, David J ^a   Singh, Anjali ^a   Trippett, Tanya ^a,b   Bell, John ^c   Forsyth, Peter ^d   Johnston, Randal N ^a   Narendran, Aru ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Atypical teratoid rhabdoid tumors (AT RT); Double deleted vaccinia virus; Neuroblastoma; Oncolytic virus; Pediatric tumors; Sarcoma

Indexed keywords

ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL ASSAY; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CHILDHOOD CANCER; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; LUNG METASTASIS; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RHABDOID TUMOR; SARCOMA; SOLID TUMOR; TUMOR XENOGRAFT; VACCINIA VIRUS; VIROTHERAPY; VIRUS REPLICATION;

ANIMALIA; VACCINIA VIRUS;

ATYPICAL TERATOID RHABDOID TUMORS (AT/RT); DOUBLE-DELETED VACCINIA VIRUS; NEUROBLASTOMA; ONCOLYTIC VIRUS; PEDIATRIC TUMORS; SARCOMA;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; INFANT; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS; NEUROBLASTOMA; ONCOLYTIC VIROTHERAPY; SARCOMA; VACCINIA VIRUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884287215     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.05.004     Document Type: Article

References (36)

1. Alain T., Lun X., Martineau Y., Sean P., Pulendran B., Petroulakis E., Zemp F.J., Lemay C.G., Roy D., Bell J.C., Thomas G., Kozma S.C., Forsyth P.A., Costa-Mattioli M., Sonenberg N. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc. Natl. Acad. Sci. U S A 2010, 107(4):1576-1581.
2. 2-terminal kinase. J.Virol. 2007, 81(14):7504-7516.
3. Bai X., Yan Y., Coleman M., Wu G., Rabinovich B., Seidensticker M., Alt E. Tracking long-term survival of intramyocardially delivered human adipose tissue-derived stem cells using bioluminescence imaging. Mol. Imaging Biol. 2011, 13(4):633-645.
4. Beer S.J., Matthews C.B., Stein C.S., Ross B.D., Hilfinger J.M., Davidson B.L. Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity invivo. Gene Ther. 1998, 5(6):740-746.
5. Bourke M.G., Salwa S., Harrington K.J., Kucharczyk M.J., Forde P.F., de Kruijf M., Soden D., Tangney M., Collins J.K., O'Sullivan G.C. The emerging role of viruses in the treatment of solid tumours. Cancer Treat. Rev. 2011, 37(8):618-632.
6. Breitbach C.J., Burke J., Jonker D., Stephenson J., Haas A.R., Chow L.Q., Nieva J., Hwang T.H., Moon A., Patt R., Pelusio A., Le Boeuf F., Burns J., Evgin L., De Silva N., Cvancic S., Robertson T., Je J.E., Lee Y.S., Parato K., Diallo J.S., Fenster A., Daneshmand M., Bell J.C., Kirn D.H. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011, 477(7362):99-102.
7. Brisac C., Téoulé F., Autret A., Pelletier I., Colbère-Garapin F., Brenner C., Lemaire C., Blondel B. Calcium flux between the endoplasmic reticulum and mitochondrion contributes to poliovirus-induced apoptosis. J.Virol. 2010, 84(23):12226-12235.
8. Chillón M., Lee J.H., Fasbender A., Welsh M.J. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies invitro. Gene Ther. 1998, 5(7):995-1002.
9. Donnelly O.G., Errington-Mais F., Prestwich R., Harrington K., Pandha H., Vile R., Melcher A.A. Recent clinical experience with oncolytic viruses. Curr. Pharm. Biotechnol. 2012, 13(9):1834-1841.
10. Friedman G.K., Pressey J.G., Reddy A.T., Markert J.M., Gillespie G.Y. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol. Ther. 2009, 17(7):1125-1135.
11. Geletneky K., Huesing J., Rommelaere J., Schlehofer J.R., Leuchs B., Dahm M., Krebs O., von Knebel Doeberitz M., Huber B., Hajda J. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer 2012, 12:99.
12. Haddad D., Chen N., Zhang Q., Chen C.H., Yu Y.A., Gonzalez L., Aguilar J., Li P., Wong J., Szalay A.A., Fong Y. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers. Ann. Surg. Oncol. 2012, 19(Suppl 3):S665-S674.
13. Hammill A.M., Conner J., Cripe T.P. Oncolytic virotherapy reaches adolescence. Pediatr. Blood Cancer 2010, 55(7):1253-1263.
14. He S., Li P., Chen C.H., Bakst R.L., Chernichenko N., Yu Y.A., Chen N., Szalay A.A., Yu Z., Fong Y., Wong R.J. Effective oncolytic vaccinia therapy for human sarcomas. J.Surg. Res. 2012, 175(2):e53-60.
15. Hengstschlager M., Mullner E., Wawra E. Thymidine kinase is expressed differently in transformed versus normal-cells - a novel test for malignancy. Int. J. Oncol. 1994, 4(1):207-210.
16. Heo J., Reid T., Ruo L., Breitbach C.J., Rose S., Bloomston M., Cho M., Lim H.Y., Chung H.C., Kim C.W., Burke J., Lencioni R., Hickman T., Moon A., Lee Y.S., Kim M.K., Daneshmand M., Dubois K., Longpre L., Ngo M., Rooney C., Bell J.C., Rhee B.G., Patt R., Hwang T.H., Kirn D.H. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. Feb 10 2013, ([Epub ahead of print]). 10.1038/nm. 3089.
17. Kirn D.H., Thorne S.H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 2009, 9(1):64-71.
18. Kirn D.H., Wang Y., Liang W., Contag C.H. Thorne SH. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res. 2008, 68(7):2071-2075.
19. Lun X., Yang W., Alain T., Shi Z.Q., Muzik H., Barrett J.W., McFadden G., Bell J., Hamilton M.G., Senger D.L., Forsyth P.A. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. 2005, 65(21):9982-9990.
20. Lun X.Q., Jang J.H., Tang N., Deng H., Head R., Bell J.C., Stojdl D.F., Nutt C.L., Senger D.L., Forsyth P.A., McCart J.A. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin. Cancer Res. 2009, 15(8):2777-2788.
21. Lun X., Chan J., Zhou H., Sun B., Kelly J.J., Stechishin O., Bell J.C., Parato K., Hu K., Vaillant D., Wang J., Liu T.C., Breitbach C., Kirn D., Senger D.L., Forsyth P.A. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol. Ther. 2010, 18(11):1927-1936.
22. Luu H.H., Kang Q., Park J.K., Si W., Luo Q., Jiang W., Yin H., Montag A.G., Simon M.A., Peabody T.D., Haydon R.C., Rinker-Schaeffer C.W., He T.C. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin. Exp. Metastasis 2005, 22(4):319-329.
23. Macy M.E., Sawczyn K.K., Garrington T.P., Graham D.K., Gore L. Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials. Curr. Oncol. Rep. 2008, 10(6):477-490.
24. Mastrangelo M.J., Maguire H.C., Eisenlohr L.C., Laughlin C.E., Monken C.E., McCue P.A., Kovatich A.J., Lattime E.C. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999, 6(5):409-422.
25. Merrick A.E., Ilett E.J., Melcher A.A. A targeted oncolytic poxvirus for the treatment of cancer. Curr. Opin. Investig. Drugs 2009, 10(12):1372-1382. JX-594.
26. Morton C.L., Houghton P.J., Kolb E.A., Gorlick R., Reynolds C.P., Kang M.H., Maris J.M., Keir S.T., Wu J., Smith M.A. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr. Blood Cancer 2010, 55(2):295-303.
27. Naik A.M., Chalikonda S., McCart J.A., Xu H., Guo Z.S., Langham G., Gardner D., Mocellin S., Lokshin A.E., Moss B., Alexander H.R., Bartlett D.L. Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates. Hum. Gene Ther. 2006, 17(1):31-45.
28. Narendran A., Coppes L., Jayanthan A., Coppes M., Teja B., Bernoux D., George D., Strother D. Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics. J.Neurooncol. 2008, 90(2):171-180.
29. Park B., Hwang T., Liu T.C., Sze D.Y., Kim J.S., Kwon H.C., Oh S.Y., Han S.Y., Yoon J.H., Hong S.H., Moon A., Speth K., Park C., Ahn Y.J., Daneshmand M., Rhee B.G., Pinedo H.M., Bell J.C., Kirn D.H. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008, 9(6):533-542.
30. Reichard R.W., Lorence R.M., Cascino C.J., Peeples M.E., Walter R.J., Fernando M.B., Reves H.M., Greager J.A. Newcastle disase virus selectively kills human tumor cells. J.Surg. Res. 1992, 52(5):448-453.
31. Rojas J.J., Thorne S.H. Theranostic potential of oncolytic vaccinia virus. Theranostics 2012, 2(4):363-373.
32. Russell S.J., Peng K.W., Bell J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012, 30(7):658-670.
33. Studebaker A.W., Kreofsky C.R., Pierson C.R., Russell S.J., Galanis E., Raffel C. Treatment of medulloblastoma with a modified measles virus. Neuro Oncol. 2010, 12(10):1034-1042.
34. Szentirmai O., Baker C.H., Lin N., Szucs S., Takahashi M., Kiryu S., Kung A.L., Mulligan R.C., Carter B.S. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 2006, 58:365-372.
35. Tumilowicz J.J., Nichols W.W., Cholon J.J., Greene A.E. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res. 1970, 30(8):2110-2118.
36. Wu Y., Lun X., Zhou H., Wang L., Sun B., Bell J.C., Barrett J.W., McFadden G., Biegel J.A., Senger D.L., Forsyth P.A. Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin. Cancer Res. 2008, 14(4):1218-1227.